Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MELK | Q14680 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | ABL1 | P00519 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | ALAD | P13716 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15988713 | 0.79 | GSK3B (0.47) | GSK3BMELKMAPTMEN1KMT2A | |
| SCHEMBL22953102 | 0.76 | GSK3B (0.48) | GSK3BMAPTMEN1KMT2AALAD | |
| SCHEMBL13116478 | 0.76 | GSK3B (0.44) | GSK3BMELKMAPTMEN1KMT2A | |
| SCHEMBL10513732 | 0.76 | GSK3B (0.44) | GSK3BMELKMAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4266714 | 0.74 | GSK3B (0.43) | GSK3BMELKMAPTMEN1KMT2A | |
| SCHEMBL27577455 | 0.73 | GSK3B (0.42) | GSK3BMELKMAPTMEN1KMT2A | |
| SCHEMBL15979708 | 0.70 | DAO (0.52) | GSK3BMAPTMEN1KMT2AALAD | |
| SCHEMBL1771045 | 0.70 | — | — | |
| SCHEMBL788121 | 0.70 | — | — | |
| SCHEMBL4945211 | 0.69 | TPMT (0.46) | GSK3BKCNH2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110198939-B | Modulators of adenosine A3 receptors | 帕罗生物制药有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-107207445-B | Adenosine A3Modulators of receptors | 帕罗生物制药有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3581572-B1 | ADENOSINE A3 RECEPTOR MODULATORS | PALOBIOFARMA SL (ES) | 2020-11-25 | — | — | EP | disclosed |
| EP-3581572-B1 | ADENOSINE A3 RECEPTOR MODULATORS | PALOBIOFARMA SL (ES) | 2020-11-25 | — | — | EP | disclosed |
| US-10744125-B2 | Adenosine A3 receptor modulators | PALOBIOFARMA, S.L. (ES) | 2020-08-18 | — | — | US | disclosed |
| US-10744125-B2 | Adenosine A3 receptor modulators | PALOBIOFARMA, S.L. (ES) | 2020-08-18 | — | — | US | disclosed |
| EP-3248964-B1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA SL (ES) | 2019-07-17 | — | — | EP | disclosed |
| US-10238637-B2 | Modulators of the adenosine A3 receptors | PALOBIOFARMA, S.L. (ES) | 2019-03-26 | — | — | US | disclosed |
| US-20180263963-A1 | MODULATORS OF THE ADENOSINE A3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2018-09-20 | — | — | US | disclosed |
| WO-2018134464-A1 | ADENOSINE A3 RECEPTOR MODULATORS | PALOBIOFARMA, S.L. (ES) | 2018-07-26 | — | — | WO | disclosed |
| EP-3248964-A1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA S.L. (ES) | 2017-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263963-A1 | MODULATORS OF THE ADENOSINE A3 RECEPTORS | ADORA3, ADORA2A, ADORA1 | GSK3B 2022/4885KCNH2 3582/4885MELK 2556/4885 |
| US-10744125-B2 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | GSK3B 1758/4885KCNH2 1708/4885MELK 2566/4885 |
| US-10238637-B2 | Modulators of the adenosine A3 receptors | ADORA3, ADORA2A, ADORA1 | GSK3B 2022/4885KCNH2 3582/4885MELK 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.